Confluent Medical Technologies announced at MD&M West that it has partnered with ATI to invest more than $50 million over the next several years in ATI’s Nitinol melt and materials conversion infrastructure. With this significant investment, which will more than triple ATI’s melt capacity for medical Nitinol, Confluent will become ATI’s fulfillment partner and provide a suite of value-add services and order-fulfillment for ATI medical Nitinol mill product.
“The growth in in neurovascular, electrophysiology, structural heart, peripheral vascular, and orthopedic device markets is driving an 18 percent growth rate (CAGR) in Nitinol demand. Given the substantial equipment and infrastructural cost needed to increase supply chain capacity, the industry has struggled to support this growth,” said Dean Schauer, CEO and president of Confluent. “Our investment in this critical infrastructure will provide the necessary mid-term and long-term melt and conversion capacity necessary to meet and support Nitinol material demand. As the most trusted supply partner for our OEM customers, Confluent is pleased to be making this investment in creating a reliable supply chain so that OEMs can continue providing life-saving devices in these specialized markets.”
“ATI is honored to partner with Confluent in producing what is literally a life-saving material,” said Rob Foster, President of ATI’s Specialty Alloys & Components business. “We appreciate the value Confluent places on our expertise and capabilities as the industry leader in Nitinol production. Confluent’s investment in ATI’s growth will ensure the stable supply of Nitinol the industry needs for growth.” The expansion at ATI’s Millersburg, Oregon facility is expected to come online in 2027.
With these expanded capabilities and capacity investments, Confluent says it will continue to provide customers with the most reliable supply chain delivering the broadest level of medical Nitinol services in mill products, hollows, tubes, wires, and components.